Target
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
3 abstracts
Abstract
Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma.Org: Pediatric Cancer Center Barcelona, Queen Mary Hospital and Hong Kong Children's Hospital, IRCCS Istituto Giannina Gaslini, Center for Pediatric and Adolescent Medicine, Riley Hospital for Children,
Abstract
Randomized phase 2 trial of personal dendritic cell (DC)-autologous tumor antigen (ATA) vaccines in newly diagnosed advanced ovary cancer.Org: University of Colorado Cancer Center, Hoag Gynecologic Oncology, Scripps Clinic/Green Hospital, University of California San Diego, Moores Cancer Center, University of California Irvine,
Abstract
Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.Org: The Clatterbridge Cancer Centre and University of Liverpool, The Institute of Cancer Research, Replimune, Department of Oncology, University of Oxford,